Last reviewed · How we verify
Antithrombin-III for Patients With Hepatic Veno-occlusive Diseases Following Hematopoietic Stem Cell Transplantation
To evaluate efficacy and safety of AT-III treatment in patients with hepatic veno-occlusive diseases following hematopoietic stem cell transplantation.
Details
| Lead sponsor | Seoul National University Hospital |
|---|---|
| Phase | Phase 2 |
| Status | UNKNOWN |
| Enrolment | 32 |
| Start date | 2013-06 |
| Completion | 2021-08 |
Conditions
- Hepatic Veno-Occlusive Disease
Interventions
- Freeze-dried Concentrated Human Antithrombin Ⅲ 500 IU
Primary outcomes
- AT-III level before 5th dose of AT-III — up to 14 days
Countries
South Korea